These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 37420216)

  • 1. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
    Dagar G; Gupta A; Masoodi T; Nisar S; Merhi M; Hashem S; Chauhan R; Dagar M; Mirza S; Bagga P; Kumar R; Akil ASA; Macha MA; Haris M; Uddin S; Singh M; Bhat AA
    J Transl Med; 2023 Jul; 21(1):449. PubMed ID: 37420216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-T cell therapy: current limitations and potential strategies.
    Sterner RC; Sterner RM
    Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
    Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
    Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
    Zuo YH; Zhao XP; Fan XX
    Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
    Chen J; Jiang H
    Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
    Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
    Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T cell therapy for lung cancer: Potential and perspective.
    Chen L; Chen F; Li J; Pu Y; Yang C; Wang Y; Lei Y; Huang Y
    Thorac Cancer; 2022 Apr; 13(7):889-899. PubMed ID: 35289077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
    Choi T; Kang Y
    Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
    Metzinger MN; Verghese C; Hamouda DM; Lenhard A; Choucair K; Senzer N; Brunicardi FC; Dworkin L; Nemunaitis J
    Oncology; 2019; 97(2):59-74. PubMed ID: 31261152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
    Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
    Front Immunol; 2022; 13():887471. PubMed ID: 35935930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cells applied to solid tumors.
    Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
    Front Immunol; 2022; 13():984864. PubMed ID: 36389701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.